Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In BioAge To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in BioAge between September 26, 2024 and January 7, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).[You may also click here for additional information]NEW YORK, Feb. 2, 2025 /PRNewswire/ -- Faruqi & Faruqi ...

NEW YORK, Feb. 02, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against BioAge Labs, Inc. (NASDAQ: BIOA) and certain of its senior executives for potential violations of the federal securities laws. If you invested in BioAge, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/bioage-labs-inc. Investors have until March 10, 2025, to ask the Court to be appointed to lead the case ...

NEW YORK, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against BioAge Labs, Inc. (NASDAQ: BIOA) and certain of its senior executives for potential violations of the federal securities laws. If you invested in BioAge, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/bioage-labs-inc. Investors have until March 10, 2025, to ask the Court to be appointed to lead the case ...

STOCKHOLM, Jan. 31, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that the European Commission has asked the Committee for Medicinal Products for Human Use (CHMP) to consider two additional questions. These questions will now be discussed at the CHMP meeting in February 2025, before the Commission can take a final decision on the Marketing Authorization Application for lecanemab as treatment for early Alzheimer's disease in the European Union. In Novembe ...

NEW YORK, Jan. 30, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of BioAge Labs, Inc. (NASDAQ: BIOA).Shareholders who purchased shares of BIOA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/bioage-labs-inc-loss-submission-form/?id=125756&from=4 CLASS PERIOD: This lawsuit is on ...

Core Viewpoint - A securities class action lawsuit has been filed against BioAge Labs, Inc. for alleged misleading statements in its IPO registration statement related to its STRIDES Phase 2 trial for azelaprag [1][2]. Group 1: Allegations Against BioAge - The lawsuit claims that BioAge made false and misleading statements regarding the potential for liver transaminitis in previous clinical trials and preclinical studies [2]. - It is alleged that BioAge misrepresented the safety concerns and expected outcomes of its STRIDES clinical trial, leading to materially false and misleading statements about the company's business and prospects [2]. Group 2: Legal Process for Investors - Investors in BioAge have until March 10, 2025, to seek appointment as lead plaintiff in the class action, representing the interests of all class members [3]. - The lead plaintiff is typically the investor or group of investors with the largest financial interest and who are representative of the class [3]. Group 3: Firm Background - Kessler Topaz Meltzer & Check, LLP is known for prosecuting class actions and has a reputation for recovering billions for victims of corporate misconduct [4].

Advancement of next-generation APJ agonists with discontinuation of azelaprag Nomination of NLRP3 inhibitor BGE-102 as a development candidate, with initial Ph1 clinical data anticipated by end of 2025 Expansion of discovery efforts based on insights from BioAge’s platform, including a target identification collaboration with Novartis and a newly announced antibody therapeutics development collaboration with Lilly ExploR&D RICHMOND, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. ("BioAge", “the ...

NEW YORK, Jan. 27, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of BioAge Labs, Inc. (NASDAQ: BIOA).Shareholders who purchased shares of BIOA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/bioage-labs-inc-loss-submission-form/?id=124878&from=4 CLASS PERIOD: This lawsuit is on ...

FDA Approval and Dosing Regimen - The FDA approved Eisai's Supplemental Biologics License Application (sBLA) for Leqembi, allowing a once every four weeks intravenous (IV) maintenance dosing for patients with mild cognitive impairment (MCI) or mild dementia due to Alzheimer's disease [1] - Patients who completed the 18-month biweekly initiation phase can transition to the 10 mg/kg once every four weeks dosing regimen [1] - The approval is based on modeling data from Phase 2 and Clarity AD studies, predicting that the new dosing regimen will maintain clinical and biomarker benefits [3] Clinical Benefits and Mechanism of Action - Leqembi reduces cognitive decline by -0.95 on the CDR-SB scale compared to a matched natural history cohort, more than double the placebo effect at 18 months (-0.45) [2] - The drug works by rapidly clearing amyloid-beta (Aβ) plaque and continuously clearing highly toxic protofibrils, addressing the progressive nature of Alzheimer's disease [2] - Discontinuation of treatment leads to reaccumulation of brain amyloid and reversion to placebo rates of clinical decline, emphasizing the importance of continuous administration [2] Global Market Approvals and Submissions - Leqembi is approved in the US, Japan, China, Great Britain, and several other markets [4] - The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending approval in November 2024 [4] - Eisai has submitted applications for approval in 17 countries and regions, including the European Union [4][10] - The FDA accepted a Supplemental Biologics License Application (BLA) for a subcutaneous autoinjector formulation with a PDUFA action date of August 31, 2025 [4][10] Collaboration and Commercialization - Leqembi is the result of a long-standing collaboration between BioArctic and Eisai, with BioArctic having the right to jointly commercialize the drug in the Nordic region pending European approval [5][13] - Eisai is responsible for clinical development, regulatory applications, and global commercialization, while BioArctic is entitled to payments for regulatory approvals, sales milestones, and royalties on global sales [5][13] Ongoing Clinical Studies - Eisai's Phase 3 AHEAD 3-45 study, investigating lecanemab in preclinical Alzheimer's disease, was fully recruited in October 2024 and is ongoing [11] - The Tau NexGen clinical study for Dominantly Inherited Alzheimer's Disease (DIAD) includes lecanemab as the backbone anti-amyloid therapy and is ongoing since January 2022 [11] About Leqembi (Lecanemab) - Lecanemab is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody targeting aggregated soluble and insoluble forms of amyloid-beta (Aβ) [7] - It is approved for treating mild cognitive impairment (MCI) and mild Alzheimer's dementia in multiple markets, with approvals based on Phase 3 data from the Clarity AD trial [8][9] - Common adverse events include infusion reactions, ARIA-H, ARIA-E, headache, and fall [9]

RADNOR, Pa., Jan. 26, 2025 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California against BioAge Labs, Inc. (“BioAge”) (NASDAQ: BIOA) on behalf of those who purchased stock pursuant and/or traceable to BioAge's registration statement for its initial public offering (“IPO”) held on or about September 26, 2024 (the “Class Period”). T ...